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Would it not be great to have a treatment for advanced lung cancer where most patients respond regardless of their tumor type or genetic profile? Would it not be great if this 
treatment could provide prompt symptom relief with mild toxicity? Better yet, what if this 
treatment was available at a fraction of the price of targeted therapies currently in clinical 
use or under development? Should not this treatment be offered to the majority of patients 
with advanced lung cancer at some point in their disease? Is it reasonable to deny patients 
such treatment, even if referral to a different specialist was required or the patient had to 
travel to receive it?
Of course, such therapy does exist and has for decades—radiation. Evidence of the 
efficacy of radiation therapy (RT) for lung cancer has existed since the 1950s. The body of 
evidence grew in the 1980s, with the advent of megavoltage radiotherapy and proliferation 
of randomized trials, proving its benefit. More recent reviews have solidified its efficacy 
in the palliative setting1 and for patients with inoperable disease.2,3 The evidence is mature 
and unequivocal.
It is puzzling, then, that there is a parallel literature on underuse of RT. In 1994 
Mackillop et al.4 was the first to publish on the large variation in RT use for non–small-cell 
lung cancer (NSCLC) in the province of Ontario, Canada. In the same year, they demon-
strated that personal beliefs, rather than knowledge, guide the management of NSCLC 
in Canada.5 Similar surveys from Italy, England, and Wales have also demonstrated that 
decisions for NSCLC are highly varied, often not in keeping with known evidence.6,7 A 
more recent survey reflects changing attitudes, with radical treatment being given more fre-
quently, but the perception of benefit or personal belief was still a strong influencing factor.8
Tyldesley et al.9 published a model estimating the need for RT based on epidemio-
logic observations of the population, and known indications for RT, to determine which 
rate is right? Follow-up work confirmed that the actual RT rate in Ontario was below the 
ideal.10 Similar observations have been made in Australia,11 New Zealand,12 and Italy.13 RT 
usage rates vary from country to country; though underuse is widespread, it is not univer-
sal.14 Furthermore, lung cancer patients are not the only ones being denied access to useful 
therapy. Similar observations have been made for breast,15 prostate,16 and cervix cancer.17
In this issue of the journal, Tovar et al.18 provide yet another example of the underuse 
of radiotherapy, this time in Spain. They go one step further and estimate the survival lost 
as a result of the underuse of RT. The main weaknesses of the study are those common to all 
studies using administrative health data: potential issues with data capture, missing clinical 
data about comorbid illness, or patient preference for therapy. These limitations may result 
in underestimation of RT use but are probably not responsible for the entire difference 
between observed and ideal rate. Regardless, the results are compelling, with more than 
250 years of survival lost in 1 year for the 7.8 million individuals in that region of Spain. 
If the lost opportunity for symptom control had also been estimated, the impact on patient 
experience would have been even more profound.
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Have we forgotten that radiation works for lung cancer? 
Most of the buzz in lung cancer these days is about targeted 
molecular agents and personalized cancer medicine—a huge 
advance for those who harbor the known mutations, but not 
a panacea for all. If RT is spoken about, the buzz is about 
stereotactic body radiotherapy (SBRT) which is of benefit to 
only a small proportion of patients. Is treatment proven worthy 
more than 20 years ago not novel enough to still be used?
To improve the use of RT, Dr. Tovar’s group suggests 
increasing the availability of RT with more linear accel-
erators. This could improve geographic accessibility and/
or wait times. They also suggest greater involvement of 
radiation oncologists in multidisciplinary clinics or tumor 
boards. We agree that lung cancer treatment decisions are 
best made in a multidisciplinary fashion, and that although, 
a linear accelerator cannot travel, a radiation oncologist can. 
A radiation oncologist is best positioned to advocate for RT 
when (s)he is an integral member of the care team and par-
ticipates in the patient’s care along the trajectory of illness. 
We would also suggest an increased presence of RT in train-
ing curricula for medical students, family physicians, gen-
eral internists, and medical oncologists. We would further 
suggest that continuing education events for lung cancer 
include radiotherapy, not just SBRT, but more traditional 
applications as well.
Thinking broadly, we must consider how we can help 
our patients best, be it with radiation, psycho–social support, 
palliative care, or the next line of systemic therapy. As lung 
cancer specialists, we need to advocate for the role of radia-
tion in the management of lung cancer to our patients and 
our colleagues to ensure patients are offered the most effec-
tive treatments with minimal toxicity, even if that is an old- 
fashioned parallel opposed pair of beams.
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